EP0381959B1 - Cyclohexanacetamid-Derivate - Google Patents

Cyclohexanacetamid-Derivate Download PDF

Info

Publication number
EP0381959B1
EP0381959B1 EP90100935A EP90100935A EP0381959B1 EP 0381959 B1 EP0381959 B1 EP 0381959B1 EP 90100935 A EP90100935 A EP 90100935A EP 90100935 A EP90100935 A EP 90100935A EP 0381959 B1 EP0381959 B1 EP 0381959B1
Authority
EP
European Patent Office
Prior art keywords
methyl
alkyl
aryl
oxo
phenylmethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP90100935A
Other languages
English (en)
French (fr)
Other versions
EP0381959A1 (de
Inventor
Gary Lee Olson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of EP0381959A1 publication Critical patent/EP0381959A1/de
Application granted granted Critical
Publication of EP0381959B1 publication Critical patent/EP0381959B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings

Definitions

  • the invention relates to [(5-oxo-2-pyrrolidinyl)methyl]cyclohexaneacetamides of the formula wherein R1 is hydrogen, lower alkyl or aryl-lower alkyl; R2 is hydrogen, lower alkyl, aryl, aryl-lower alkyl, wherein R5 and R6 are hydrogen, lower alkyl or aryl-lower alkyl; R3 and R4, independently, are hydrogen, lower alkyl or aryl-lower alkyl; and enantiomers, diastereomers, and racemates thereof, and, when R2 is pharmaceutically acceptable acid addition salts thereof.
  • the compounds of formula I exhibit cognitive enhancement and antiamnestic activity and are therefore useful, for example, in treating memory deficits associated with Alzheimer's disease or age-associated memory impairment.
  • lower alkyl denotes a straight or branched chain saturated hydrocarbon containing 1 to 7 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, butyl, t-butyl, neopentyl, pentyl, heptyl and the like.
  • lower alkoxy denotes an alkyl ether group in which the lower alkyl group is as described above, for example, methoxy, ethoxy, propoxy, pentyloxy, isobutoxy, heptoxy and the like.
  • aryl-lower alkyl denotes a lower alkyl substituted by an aryl group wherein aryl is as described below, particularly phenyl or phenyl bearing one or two substituents independently selected from the group consisting of halogen, trifluoromethyl and lower alkyl.
  • aryl-lower alkyl are benzyl, 2-phenylethyl, 2-chlorobenyl and the like.
  • halogen denotes bromine, chlorine, fluorine or iodine.
  • aryl denotes phenyl or naphthyl, or phenyl or naphthyl bearing one or two substituents independently selected from the group consisting of halogen, trifluoromethyl, lower alkyl, and lower alkoxy.
  • a preferred group of compounds of the invention comprise those compounds of formula I wherein R1 is hydrogen, lower alkyl or aryl-lower alkyl; R2 is hydrogen, lower alkyl or wherein R6 is hydrogen or aryl-lower alkyl; R3 and R4, independently, are hydrogen or lower alkyl and enantiomers and, when R2 is pharmaceutically acceptable acid addition salts thereof.
  • a more preferred group of compounds of the invention comprise those compounds of formula I wherein R1 is hydrogen or aryl-lower alkyl; R2 is lower alkyl or wherein R6 is hydrogen or aryl-lower alkyl; R3 and R4 are hydrogen and, when R2 is pharmaceutically acceptable acid addition salts thereof.
  • a still more preferred group of compounds of the invention comprise compounds of the formula wherein R2' is hydrogen, alkyl, or aryl-lower alkyl; and R1, R3, and R4 are as previously described, and their enantiomers and racemates.
  • R1 is hydrogen or aryl-lower alkyl
  • R2' is hydrogen or lower alkyl
  • R3 and R4, independently, are hydrogen and enantiomers thereof.
  • R2'' is R1, R3, R4, R5 and R6 are as previously described, and their enantiomers and racemates and pharmaceutically acceptable acid addition salts thereof.
  • Particularly preferred are compounds of formula I-B wherein R1 is hydrogen or aryl-lower alkyl; R 2'' is wherein R6 is hydrogen or aryl lower-alkyl and R3 and R4 are hydrogen, and enantiomers, and pharmaceutically acceptable acid addition salts thereof.
  • Most preferred compounds of formula I of the invention are: [1 R , 3 R , 5 S , 5(2 S )]-3-methyl-5-[[5-oxo-1-(phenylmethyl)-2-pyrrolidinyl]methyl]cyclohexaneacetamide; [1 R , 3 R , 5 S , 5(2 S )]-3-methyl-5-[[5-oxo-2-pyrrolidinyl]methyl]cyclohexaneacetamide; [1 R , 3 R , 5 S , 5(2 S )]-3-methyl-5-[[5-oxo-1-[(4-methoxyphenyl)methyl]-2-pyrrolidinyl]methyl]cyclohexaneacetamide; [1 R , 3 R , 5 S , 5(2 S )]-3-methyl-5-[[5-oxo-1-[(4-chlorophenyl)methyl]-2-pyrrolidinyl]-methyl]cyclo
  • Preferred compounds of the formula I are the following: [1 R , 3 R , 5 S , 5(2 S )]-3-methyl-5-[[5-oxo-1-[(3-methylphenyl)methyl]-2-pyrrolidinyl]-methyl]-cyclohexaneacetamide; [1 R , 3 R , 5 S , 5(2 S )]-3-methyl-5-[[5-oxo-1-methyl-2-pyrrolidinyl]-methyl]-cyclohexaneacetamide; [1 R , 3 R , 5 S , 5(2 S )]-3-phenylmethyl-5-[[5-oxo-1-(phenylmethyl)-2-pyrrolidinyl]-methyl]cyclohexaneacetamide; [1 R , 3 R , 5 S , 5(2 S )]-3-methyl-5-[[5-oxo-1-[2-(phenylethyl)]-2-pyrrolidiny
  • the compounds of formula I of the invention may exist as the R and S enantiomers at each of the asymmetric centers, mixtures thereof, or as single diastereomers or single enantiomers. Single diastereomers and single enantiomers are preferred.
  • the compounds of formula I can be prepared as set forth in Schemes I to XV and as further described.
  • the process set forth in Scheme I comprises the preparation of the intermediate, ( S )-5-oxo-1-(phenylmethyl)-2-pyrrolidineacetaldehyde ( 10a ).
  • L-glutamic acid ( 3 ) can be reductively alkylated with benzaldehyde and sodium borohydride to yield the N-(1-phenylmethyl)-L-glutamic acid ( 4a ).
  • optical purity of ( S )-5-(hydroxymethyl)-1-(phenylmethyl)-2-pyrrolidinone ( 6 ) can be established by formation of the ester derived from ( S )-(-)- ⁇ -methoxy- ⁇ -(trifluoromethyl)phenylacetic acid ((-)-MTPA) following the procedure of Mosher, et al.[ J . Org. Chem. 1969 , 34 , 2543]. Conversion of ( 6 ) to the tosylate ( 7 ) was accomplished by treatment with p-toluenesulfonyl chloride and 4-dimethylaminopyridine.
  • the aldehyde, ( S )-5-oxo-1-(phenylmethyl)-2-pyrrolidineacetaldehyde ( 10a ) is treated with ethyl triphenylphosphoranylideneacetate in toluene at 90 °C to give the unsaturated ester ( 11 ).
  • Treatment of ( 11 ) with ethyl acetoacetate and with sodium ethoxide, followed by hydrolysis and decarboxylation yields the diketone ( 12 ).
  • This compound exists as a single enantiomer when derived from a single enantiomer of the aldehyde ( 10a ).
  • the process set forth in Scheme III comprises the preparation of compounds of the formula I-A-1 and I-A-2 , starting from (5 S , 1 R )-5-[(3-ethoxy-5-oxo-3-cyclohexen-1-yl)methyl]-1-(phenylmethyl)-2-pyrrolidinone ( 13a ).
  • the ketoenol ether ( 13a ) is reacted with methyllithium, followed by acid hydrolysis to yield the enone ( 14a ).
  • Treatment of ( 14a ) with ethyl trimethylsilylacetate and lithium diisopropylamide gives the dienoic ester ( 15 ).
  • the process set forth in Scheme IV comprises the preparation of the intermediate [1 S , 5 S , 5(2 S )]-3-oxo-5-[[5-oxo-1-(phenylmethyl)-2-pyrrolidinyl]methyl]cyclohexaneacetic acid ethyl ester ( 18a ), starting from [5 S , (1 S )]-5-[(3-ethoxy-5-oxo-3-cyclohexen-1-yl)methyl]-1-(phenylmethyl)-2-pyrrolidinone ( 13b ).
  • the ketoenolether of formula ( 13b ) is treated with lithio ethyl trimethylsilylacetate (prepared from ethyl trimethylsilylacetate and lithium diisopropylamide), and then hydrolyzed with aqueous acid to yield the enone ester ( 17 ). Hydrogenation of ( 17 ), for example, over palladium on carbon, produces the saturated ketoester ( 18a ), with the acetic ester side chain predominantly cis to the oxopyrrolidinylmethyl chain.
  • the compound of formula ( 18a ) has the S , S , S - configuration. wherein R3 and R4 are as previously described.
  • the process set forth in Scheme V comprises the preparation of intermediates of the formula wherein R3 and R4 are as previously described, starting from [1 S , 5 S , 5(2 S )]-3-oxo-5-[[5-oxo-1-(phenylmethyl)-2-pyrrolidinyl]methyl]cyclohexaneacetic acid ethyl ester ( 18a ) and [2-[(phenylmethyl)amino]ethenyl]phosphonic acid diethyl ester ( 19a ). More particularly, in Reaction Scheme V, a directed aldol condensation [W.
  • the process set forth in Scheme VI comprises the preparation of compounds of the formula I-B-1 , I-B-2 , and I-B-3 , starting from a compound of the formula as hereinbefore described. More particularly, in Scheme VI, an unsaturated imidazole amide of formula II-B can be reduced in stages to saturate the double bond and to remove the 1-(phenylmethyl) groups on the imidazole and pyrrolidinone rings selectively. For example, hydrogenation of a compound of formula II-B over 10% palladium on carbon in ethanol at room temperature and at 1 atm pressure yields the corresponding imidazole amides of formula I-B-1 .
  • the process set forth in Scheme VII comprises the preparation of compounds of the formula I-A-3 , starting from (5 S , 1 R )-5-[(3-methyl-5-oxo-3-cyclohexen-1-yl)methyl]-1-(phenylmethyl)-2-pyrrolidinone. More particularly, in Scheme VII, the enone ( 14a ) is converted to the corresponding ketal ( 23a ) using ethylene glycol and p-toluenesulfonic acid catalyst. Sodium-ammonia reduction of the N-1-(phenylmethyl) ketal ( 23a ) removes the 1-(phenylmethyl) group, giving the lactam ketal ( 23b ).
  • the alkylating agent used in this reaction may be an alkyl halide, for example, methyl iodide, ethyl bromide, butyl bromide and the like; or an aryl-lower alkyl halide, for example, 2-(phenyl-ethyl) bromide, 4-methoxy-1-(phenylmethyl) chloride, 1-(phenylmethyl) bromide and the like.
  • Hydrolysis of the ketal group in ( 23c ) is accomplished by stirring with an acidic ion exchange resin, for example, Amberlyst-15, in aqueous acetone to yield the corresponding substituted enone ( 14b ).
  • an acidic ion exchange resin for example, Amberlyst-15
  • the conversion of a compound of the formula ( 14b ) to the corresponding compound of formula I-A-3 is accomplished as previously described in Formula Scheme III. wherein R1,R3, and R4 are as previously described, and R2''' is alkyl, aryl, or aryl-lower alkyl.
  • the process set forth in Scheme VIII comprises the preparation of compounds of the formula I-A-4 , starting from (5 S , 1 R )-5-[(3-ethoxy-5-oxo-3-cyclohexen-1-yl)methyl]-1-(phenylmethyl)-2-pyrrolidinone ( 13a ). More particularly, in Scheme VIII, the ketoenol ether ( 13a ) is treated with an alkyllithium reagent such as methyllithium, phenyllithium, n-butyllithium and the like, or a Grignard reagent, such as methylmagnesium bromide and the like, and then hydrolyzed with aqueous acid to yield an enone of formula ( 14c ).
  • an alkyllithium reagent such as methyllithium, phenyllithium, n-butyllithium and the like
  • a Grignard reagent such as methylmagnesium bromide and the like
  • the process set forth in Scheme IX comprises the preparation of compounds of formula I-A-5 and I-B-4 starting from L-glutamic acid ( 3 ). More particularly, in Scheme IX, L-glutamic acid may be reductively alkylated with an aldehyde to yield an N-substituted glutamic acid derivative of the formula ( 4b ). This reductive alkylation may be performed under standard conditions [see, for example, P. Quitt, et al., Helv. Chim. Acta , 1963 , 46 , 327 - 333]. Remaining conversions are performed as described in Schemes I, II, III, and IV-VI. wherein R5' is alkyl or aryl-lower alkyl and R1′, R3, R6′ and R4 are as previously described.
  • Scheme X comprises the preparation of compounds of the formula I-B-5 and I-B-7 starting from a compound of the formula I-B-4 , and the further conversion of the compound of formula I-B-5 to the compound of formula I-B-6 . More particularly, in Scheme X, an imidazole amide of formula I-B-4 is treated with acetyl chloride in the presence of a base, such as 4-dimethyl-aminopyridine and the like, at a temperature in the range of room temperature to about 50 °C to yield a mixture of the corresponding acetates of formulas 24a and 24b .
  • a base such as 4-dimethyl-aminopyridine and the like
  • the mixture is then treated with an alkyl or aryl-lower alkyl halide, for example, with methyl iodide followed by alkaline hydrolysis, to yield the corresponding compound I-B-5 or I-B-7 .
  • an alkyl or aryl-lower alkyl halide for example, with methyl iodide followed by alkaline hydrolysis
  • the mixture of compounds of formulas I-B-5 and I-B-7 may be separated, for example, by chromatography, to yield the individual compounds, or the acetates 24a and 24b can be separated prior to treatment with the halide to provide the individual compounds of the formula I-B-5 and I-B-7 .
  • Conversion of the compound of formula I-B-5 wherein R1′ is benzyl may be accomplished by treatment with sodium in liquid ammonia to yield a compound of the formula I-B-6 . wherein R1′, R3, R4 and R6′ are as previously described.
  • the process set forth in Scheme XI comprises the preparation of compounds of the formula I-B-7 starting from diethylphosphonoacetaldehyde and a primary amine. More particularly, in Scheme XI, diethylphosphonoacetaldehyde may be condensed with a primary amine of the formula H2N-R6′ to form a phosphonoenamine of the formula ( 19b ). A number of these compounds are found to exist in equilibrium with tautomeric forms in which the imine form, rather than the enamine form, predominates. [See, for example, W. Nagata, et al., Organic Syntheses , 1973 , 53 , 44].
  • the process set forth in Scheme XII comprises the preparation of compounds of the formula I-A-6 , starting from (5 S , 1 R )-5-[(3-ethoxy-5-oxo-3-cyclohexen-1-yl)methyl]-1-(phenylmethyl)-2-pyrrolidinone ( 13a ). More particularly, in Scheme XII, hydride reduction of the ketoenol ether 13a with a selective hydride, for example, sodium borohydride-cerium chloride [Luche, J.L.; Rodriguez-Hahn, L.; Crabbe, P. J. Chem. Soc. Chem. Commun ., 1978 , 601-602] followed by acid hydrolysis gives the enone of formula 14e . The methods for the further transformations of 14e to the corresponding compound of formula I-A-6 are described in Schemes VII and III. wherein R1′, R3, and R4 are as hereinbefore described; Ar is an aryl group.
  • Scheme XIII comprises an alternative method for the preparation of compounds of the formula I-A-4 . More particularly, in Scheme XIII, a compound of the formula 18b is reacted with a Wittig reagent derived from an aryl-methyl halide, for example, benzyltriphenylphosphorane, or a Peterson reagent, for example benzyltrimethylsilyllithium, in an inert organic solvent, such as toluene or tetrahydrofuran, at a temperature of from about 25 °C to reflux (for the Wittig reagent) or about -70 °C to about room temperature (for the Peterson reagent) to yield the alkylidene compound of the formula III-A-1 .
  • a Wittig reagent derived from an aryl-methyl halide
  • benzyltriphenylphosphorane or a Peterson reagent, for example benzyltrimethylsilyllithium
  • This product is formed as a mixture of E - and Z -isomers.
  • the ester compound of formula III-A-1 is converted to the amide compound III-A-2 following the procedures described in Scheme V for the conversion of (22) to II-B , that is, by saponification of the ethyl ester III-A-1 and formation of the active ester with, for example, ethyl chloroformate, followed by treatment with ammonia, a primary or secondary amine of the formula R3R4NH to give the corresponding compounds of the formula III-A-2 .
  • Scheme XIV describes a general procedure for the preparation of a compound of formula I-A.
  • a compound of formula A or an acyl halide, mixed anhydride, or active ester thereof is treated with an amine of the formula R3R4NH, wherein R3 and R4 are as previously described, to give a compound of formula I-A.
  • This reaction is further described and exemplified in Scheme III. wherein R1′, R3, R4, R5′, and R6′ are as previously described, and Z is aryl or wherein R1′, R3, R4, R5′, and R6′ are as previously described, and Z is aryl or
  • Scheme XV describes a general procedure for the preparation of compounds of formula I , further characterized by the formulas C, D, E, F, G, H, and J .
  • an unsaturated compound of formula B is first reduced by catalytic hydrogenation, for example, at 1 atmosphere of hydrogen over a palladium catalyst at room temperature to afford a saturated compound of the formula C .
  • Z in the compound of the formula C is an aryl group
  • the compound of formula D may be prepared by removal of the substituent R1′ when that group is benzyl, for example, by reduction with sodium in liquid ammonia.
  • Z in the compound of the Formula C is a compound of the formula E may be prepared by removal of the group R6′, for example, when R6′ is benzyl, it may be removed by catalytic hydrogenolysis over palladium catalysts at temperatures and pressures that are higher than those used for the hydrogenation of compounds of the formula B .
  • R6′ is an alkyl group
  • R1′ is a benzyl group
  • reduction of the compound of formula C with, for example, sodium in liquid ammonia affords the compound of formula F .
  • Compounds of the formula G may be prepared from compounds of the formula E when R1′ is benzyl by reduction, for example, with sodium in liquid ammonia.
  • compounds of the formula H may be prepared by alkylation of the imidazole ring of a compound of the formula E .
  • a compound of the formula J may be prepared from a compound of the formula H by removal of the R1′ group, for example, when R1′ is a benzyl group, by reduction of the compound of formula H with, for example, sodium in liquid ammonia.
  • the reactions and processes described in Scheme XV are further described and exemplified in Schemes V, VI, IX, X, XI, and XIII, and constitute an aspect of this invention.
  • any intermediate prepared in Schemes I-XV may be isolated utilizing known procedures, for example, precipitation, crystallization, chromatography or the like, prior to use in the next reaction step.
  • the end-products of formula I are isolated by similar known procedures.
  • the above compounds of formula I form pharmaceutically acceptable addition salts with, for example, both pharmaceutically acceptable organic and inorganic acids, such as acetic acid, succinic acid, formic acid, methanesulfonic acid, p-toluenesulfonic acid, hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid and the like.
  • pharmaceutically acceptable organic and inorganic acids such as acetic acid, succinic acid, formic acid, methanesulfonic acid, p-toluenesulfonic acid, hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid and the like.
  • the compounds of formula I exhibit central nervous system activity.
  • the compounds of formula I exhibit cognitive enhancement and antiamnestic activity in warm-blooded mammals.
  • the compounds of formula I are useful in treating psychogeriatric disorders, for example, in treating memory deficits associated with age-associated memory impairment or Alzheimer's disease.
  • the activity of the compounds of formula I which makes them useful in treating psychogeriatric disorders can be demonstrated in warm-blooded animals, in accordance with known procedures, as hereinafter set forth.
  • test animals were male C57Bl/10 mice, weighing 17-21 grams at the time of testing. Mice were housed in groups of 10 and had ad lib access to food and water. Mice of this strain appear to be deficient in learning the water maze task and are therefore suitable for use in drug evaluation.[Symons, J.P., Davis, R.E., and Marriott J.G. Life Sciences , 1988 , 42 , 375-383.]
  • the Morris water maze task requires an animal to attend to spatial cues in order to locate the position of a hidden platform submerged underwater.
  • the maze consisted of a 60 cm x 60 cm x 60 cm transparent plexiglas chamber filled to a depth of 30 cm, leaving 30 cm of wall extended up from the water surface.
  • the water was made opaque by the addition of powdered milk. The water temperature was maintained at 20 °C.
  • distal cues i.e., standard room objects
  • proximal cues that is, 20 cm x 22 cm unique black and white patterns pasted to the center of each of the four walls of the maze
  • the submerged platform, 8 x 8 cm, 1 cm below the water's surface was positioned near one of the four corners of the maze.
  • Each animal was given four consecutive trials (maximum of 2 min/trial, and a 10 sec intertrial interval) to locate the position of the hidden platform. On each trial the animal was placed into the water at the opposite corner to that of the submerged platform. Between trials animals were removed from the water and placed on a dry surface under a heat lamp before the start of the next trial. The time required for each animal to locate the platform on each of the four trials was recorded (latency). The mean total latency of the four trials were used as the score for a given animal.
  • TRH thyrotropin releasing hormone, pGlu-His-ProNH2
  • mice received 10 ml/kg of body weight.
  • a group of mice in each of the experiments with test compounds received a 0.1 mg/kg dose of TRH and thus served as a positive control treatment condition.
  • Time-Response (PO) Compound E 30-60 min. Time-Response (PO) Compound A - [1 R , 3 R , 5 S , 5(2 S )]-3-Methyl-5-[[5-oxo-2-pyrrolidinyl]methyl]-cyclohexaneacetamide Compound B - [1 R , 3 R , 5 S , 5(2 S )]-3-Methyl-5-[[5-oxo-1-(phenylmethyl)-2-pyrrolidinyl]-methyl]cyclohexaneacetamide Compound C - [1 S , 3 R , 5(2 S ), 5 S ]-3-[[1-Phenylmethyl)-1H-imidazol-5-yl]-methyl]-5-[[5-oxo-1-(phenylmethyl)-2-pyrrolidinyl]-methyl]- cyclohexaneacetamide Compound D - [
  • a composition containing a therapeutically effective amount of a compound of formula I , an enantiomer, a diastereomer or a racemate or a salt thereof can be administered by methods well known in the art.
  • a compound of formula I , or a salt thereof can be administered either singly or with other therapeutic agents.
  • oral administration they can be administered in the form of tablets, capsules, for example, in admixture with talc, starch, milk sugar or other inert ingredients, that is, pharmaceutically acceptable carriers, or in the form of aqueous solutions, suspensions, elixirs or aqueous alcoholic solutions, for example, in admixture with sugar or other sweetening agents, flavoring agents, colorants, thickeners and other conventional pharmaceutical excipients.
  • parenteral administration they can be administered in solution or suspension, for example, as an aqueous or peanut oil solution or suspension using excipients and carriers conventional for this mode of administration.
  • the dose of a compound of formula I or a salt thereof to be administered and the frequency of administration will be dependent on the potency and duration of activity of the particular compound of formula I or salt thereof to be administered and on the route of administration, as well as the severity of the condition, age of the mammal to be treated and the like.
  • Oral doses of a compound of formula I or a salt thereof contemplated for use in practicing the invention are in the range of from about 0.05 to about 200 mg per day, preferably from about 0.5 to about 20 mg either as a single dose or in divided doses.
  • L-Glutamic acid, monosodium salt 250 g, 1.33 mol was added at room temperature to a solution of sodium hydroxide (53.6 g, 1.34 mol) in 550 mL of water.
  • sodium hydroxide 53.6 g, 1.34 mol
  • benzaldehyde 142.3 g, 1.34 mol was added in portions, keeping the temperature at 10 - 15 °C.
  • the mixture was stirred for 30 min, and another portion of benzaldehyde (7.5 g, 0.07 mol) was added. After 10 min, a second portion of sodium borohydride (3.7 g, 0.10 mol) was added as before.
  • optical purity of the ( S )-5-(hydroxymethyl)-1-(phenylmethyl)-2-pyrrolidinone was established by formation of the ester derived from ( S )-(-)- ⁇ -methoxy- ⁇ -(trifluoromethyl)phenylacetic acid ((-)-MTPA) following the procedure of Mosher, et al. ( J. Org. Chem. 1969 , 34 , 2543).
  • the diastereomeric mixture was prepared as a racemate, starting from racemic 1-(phenylmethyl)-5-(2-propenyl)-2-pyrrolidinone.
  • the less polar diastereomer was recrystallized from ethyl acetate-hexane to give crystals suitable for X-ray analysis, mp 112-113 °C.
  • Intensity data were measured on a Hilger-Watts diffractometer (Ni-filtered, Cu Ka radiation, q -2q scans, pulse-height discrimination). The size of the crystal used for data collection was approximately 0.12 x 0.15 x 0.85 mm; the data were not corrected for absorption. Of the 1106 independent reflections for q ⁇ 57°, 1063 were considered to be observed [I > 2.5s (I)].
  • the structure was solved by a multiple-solution procedure (G. Germain, P. Main, and M. M. Woolfson, Acta Cryst . 1971 , A27 , 368) and was refined by a full-matrix least squares.
  • anisotropic thermal parameters were used for the nonhydrogen atoms and isotropic temperature factors were used for structure factor calculations but their parameters were not refined.
  • the final difference map has no peaks greater than ⁇ 0.2 e A ⁇ 3.
  • the mixture was stirred and allowed to warm slowly to 0 °C, and was maintained at 0 °C while ammonia was bubbled into the solution for 20 min.
  • the white suspension was stirred for 1 h at 0 °C, then allowed to warm to room temperature.
  • the mixture was filtered to remove the ammonium chloride precipitate, and concentrated on a rotary evaporator.
  • the residue was chromatographed on silica gel (dry column), eluting with the lower phase of a mixture prepared by shaking chloroform, methanol, water, and acetic acid together in a 9:3:1:0.6 ratio.
  • the crude product was chromatographed on silica gel (dry column), eluting with the lower phase of a mixture prepared by shaking chloroform, methanol, water, and acetic acid together in a 9:3:1:0.6 ratio.
  • the chromatography fractions were washed with saturated sodium bicarbonate and dried over Na2SO4 prior to evaporation to give 0.31 g of [1 S , 3 R , 5(2 S )-5 S ]-5-[[5-oxo-1-(phenylmethyl)-2-pyrrolidinyl]methyl]-3-[[1-(phenylmethyl)-1H-imidazol-5-yl]methyl]cyclohexaneacetamide, together with 0.21 g of recovered starting material.
  • the combined extracts were washed with brine, dried over sodium sulfate, and evaporated to give 0.055 g of crude acetate.
  • the crude product was chromatographed on silica gel, eluting with the lower phase of a mixture prepared by shaking 90 parts chloroform, 15 - 30 parts methanol, 10 parts water, and 6 parts of acetic acid to give the acetylated imidazole compounds.
  • the mixture (5 mg) was treated with excess methyl iodide in acetonitrile at reflux for 2 h, followed by evaporation of the solvent and warming the residue with 2.5N sodium hydroxide at reflux for 30 min.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Packging For Living Organisms, Food Or Medicinal Products That Are Sensitive To Environmental Conditiond (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (30)

  1. Ein Verfahren zur Herstellung von Verbindungen der Formel
    Figure imgb0125
     worin
    R₁   Wasserstoff, (C₁-C₇)Alkyl oder Aryl(C₁-C₇)alkyl;
    R₂   Wasserstoff, (C₁-C₇)Alkyl, Aryl, Aryl(C₁-C₇)alkyl,
    Figure imgb0126
    R₅ und R₆   Wasserstoff, (C₁-C₇)Alkyl oder Aryl(C₁-C₇)alkyl; und
    R₃ und R₄   unabhängig voneinander Wasserstoff, (C₁-C₇)Alkyl oder Aryl(C₁-C₇)alkyl bedeuten, und worin "Aryl" allein oder in "Aryl(C₁-C₇)alkyl" Phenyl oder Naphthyl sein kann und diese durch eine oder zwei Gruppen substituiert sein können, die unabhängig voneinander ausgewählt sind aus der Gruppe Halogen, Trifluormethyl, (C₁-C₇)Alkyl und (C₁-C₇)Alkoxy; oder ein Enantiomer, Diastereomer oder Racemat davon, und falls R₂
    Figure imgb0127
    bedeutet, ein pharmazeutisch annehmbares Säureadditionssalz davon, dadurch gekennzeichnet, dass man
    a) eine Verbindung der Formel
    Figure imgb0128
     worin R₁ und R₂ die oben angegebene Bedeutung haben oder ein Acylhalogenid, ein gemischtes Anhydrid oder einen aktiven Ester davon mit einem Amin der Formel



            R₃R₄NH



    worin R₃ und R₄ die in Anspruch 1 angegebene Bedeutung haben, umsetzt, oder
    b) eine Verbindung der Formel
    Figure imgb0129
     worin Z Aryl oder
    Figure imgb0130
     R₁' (C₁-C₇)Alkyl oder Aryl(C₁-C₇)alkyl, R₆' (C₁-C₇)Alkyl oder Aryl(C₁-C₇)alkyl bedeuten und R₃ und R₄ die in Anspruch 1 angegebene Bedeutung haben, hydriert, oder
    c) eine Verbindung der Formel I, worin R₁ und/oder R₅ oder R₆ Benzyl bedeutet, debenzyliert, oder
    d) ein Stickstoffatom der Imidazoyl-Gruppe einer Verbindung der Formel I, worin R₂ (1H-imidazol-5-yl)methyl) bedeutet, mit einer (C₁-C₇)Alkyl- oder Aryl(C₁-C₇)alkyl-Gruppe substituiert, und
    e) eine Verbindung der Formel I in Form eines Enantiomeres, eines Racemates oder einer Mischung von Diastereomeren oder Racematen isoliert, und
    f) erwünschtenfalls, eine Verbindung der Formel I, worin R₂
    Figure imgb0131
     bedeutet, in ein pharmazeutisch annehmbares Säureadditionssalz überführt.
  2. Ein Verfahren zur Herstellung gemäss Anspruch 1, worin R₂ verschieden von Aryl ist und "Aryl" in "Aryl(C₁-C₇)alkyl" Phenyl oder ein durch eine oder zwei Gruppen substituiertes Phenyl bedeutet, die unabhängig voneinander ausgewählt sind aus der Gruppe Halogen, Trifluormethyl und (C₁-C₇)Alkyl.
  3. Ein Verfahren gemäss Anspruch 1 oder 2 zur Herstellung einer Verbindung der Formel I, worin R₁ Wasserstoff, (C₁-C₇)Alkyl oder Aryl(C₁-C₇)alkyl und R₂ Wasserstoff, (C₁-C₇)Alkyl oder
    Figure imgb0132
     R₆ Wasserstoff oder Aryl(C₁-C₇)alkyl und R₃ und R₄, unabhängig voneinander Wasserstoff oder (C₁-C₇)Alkyl bedeuten.
  4. Ein Verfahren gemäss Anspruch 3 zur Herstellung einer Verbindung der Formel I, worin R₁ Wasserstoff oder Aryl(C₁-C₇)alkyl, R₂ (C₁-C₇)Alkyl oder
    Figure imgb0133
     R₆ Wasserstoff oder Aryl(C₁-C₇)alkyl und R₃ und R₄ Wasserstoff bedeuten.
  5. Ein Verfahren gemäss Anspruch 1 oder 2 zur Herstellung einer Verbindung der Formel
    Figure imgb0134
     worin R₁ Wasserstoff, (C₁-C₇)Alkyl oder Aryl(C₁-C₇)alkyl; R₂' Wasserstoff, (C₁-C₇)Alkyl oder Aryl(C₁-C₇)alkyl und R₃ und R₄ unabhängig voneinander Wasserstoff, (C₁-C₇)Alkyl oder Aryl(C₁-C₇)alkyl bedeuten.
  6. Ein Verfahren gemäss Anspruch 5 zur Herstellung einer Verbindung der Formel I-A, worin R₁ Wasserstoff oder Aryl-(C₁-C₇)alkyl; R₂ Wasserstoff oder (C₁-C₇)Alkyl und R₃ und R₄ Wasserstoff bedeuten oder ein Enantiomer davon.
  7. Ein Verfahren gemäss Ansprüchen 1 oder 2 zur Herstellung einer Verbindung der Formel
    Figure imgb0135
     worin R₁ Wasserstoff, (C₁-C₇)Alkyl oder Aryl(C₁-C₇)alkyl; R₂''
    Figure imgb0136
     R₅ und R₆ Wasserstoff, (C₁-C₇)Alkyl oder Aryl(C₁-C₇)alkyl und R₃ und R₄ unabhängig voneinander Wasserstoff, (C₁-C₇)Alkyl oder Aryl(C₁-C₇)alkyl bedeuten oder ein Enantiomer oder Racemat davon.
  8. Ein Verfahren gemäss Anspruch 7 zur Herstellung einer Verbindung der Formel I-B, worin R₁ Wasserstoff oder Aryl(C₁-C₇)alkyl; R₂''
    Figure imgb0137
     R₆ Wasserstoff oder Aryl(C₁-C₇)alkyl und R₃ und R₄ Wasserstoff bedeuten.
  9. Ein Verfahren gemäss Anspruch 1 zur Herstellung von [1R,3R,5S,5(2S)]-3-Methyl-5-[[5-oxo-1-(phenylmethyl)-2-pyrrolidinyl]-methyl]-cyclohexan-acetamid.
  10. Ein Verfahren gemäss Anspruch 1 zur Herstellung von [1R,3R,5S,5(2S)]-3-Methyl-5-[[5-oxo-2-pyrrolidinyl]-methyl]-cyclohexan-acetamid.
  11. Ein Verfahren gemäss Anspruch 1 zur Herstellung von [1R,3R,5S,5(2S)]-3-Methyl-5-[[5-oxo-1-[(4-methoxyphenyl)methyl]-2-pyrrolidinyl]methyl]cyclohexan-acetamid.
  12. Ein Verfahren gemäss Anspruch 1 zur Herstellung von [1R,3R,5S,5(2S)]-3-Methyl-5-[[5-oxo-1-[(4-chlorphenyl)methyl]-2-pyrrolidinyl]methyl]cyclohexan-acetamid gemäss Anspruch 1.
  13. Ein Verfahren gemäss Anspruch 1 zur Herstellung von [1S,3R,5(2S)],5S]-3-[[1-Phenylmethyl)-1-H-imidazol-5-yl]methyl]-5-[[5-oxo-1-(phenylmethyl)-2-pyrrolidinyl]methyl]cyclohexan-acetamid.
  14. Ein Verfahren gemäss Anspruch 1 zur Herstellung von [1S,3R,5(2S)],5S]-3-[(1H-Imidazol-5-yl)methyl]-5-[[5-oxo-1-(phenyl-methyl)-2-pyrrolidinyl]methyl]cyclohexan-acetamid.
  15. Ein Verfahren gemäss Anspruch 1 zur Herstellung von [1S,3R,5(2S)],5S]-3-(1H-Imidazol-5-yl)methyl-5-[(5-oxo-2-pyrrolidinyl)-methyl]-cyclohexan-acetamid.
  16. Ein Verfahren gemäss Anspruch 1 zur Herstellung von [1R,3S,3(2S)]-3-[[5-Oxo-1-(phenylmethyl)-2-pyrrolidinyl]-methyl]-cyclohexan-acetamid.
  17. Ein Verfahren gemäss Anspruch 1 zur Herstellung von [1S,3R,5(2S),5S]-3-[(1H-Imidazol-5-yl)methyl]-5-[[5-oxo-1-(phenyl-methyl)-2-pyrrolidinyl]methyl]cyclohexan-N-methylacetamid.
  18. Ein Verfahren gemäss Anspruch 1 zur Herstellung von [1S,3R,5(2S),5S]-3-[[1-(Phenylmethyl)-1H-imidazol-5-yl)methyl]-5-[[5-oxo-1-(phenylmethyl)-2-pyrrolidinyl]methyl]cyclohexan-N-methylacetamid.
  19. Ein Verfahren gemäss Anspruch 1 zur Herstellung von [1S,3R,5(2S),5S]-3[[1-(Methyl-1H-imidazol-5-yl)methyl]-5-[[5-oxo-1-(phenylmethyl)-2-pyrrolidinyl]methyl]cyclohexan-acetamid.
  20. Ein Verfahren gemäss Anspruch 1 zur Herstellung von [1S,3R,5(2S),5S]-3-[1(Methyl-1H-imidazol-4-yl)methyl]-5-[[5-oxo-1-(phenylmethyl)-2-pyrrolidinyl]methyl]cyclohexan acetamid.
  21. Ein Verfahren zur Herstellung eines Medikaments, vorzugsweise zur Behandlung von Gedächtnisstörungen im Zusammenhang mit der Alzheimer-Krankheit oder von altersbedingten Verschlechterungen des Erinnerungsvermögens, gekennzeichnet dadurch, dass man eine Verbindung der Formel I gemäss Anspruch 1 oder ein pharmazeutisch annehmbares Salz davon zusammen mit einem therapeutisch inerten Excipiens in eine galenische Darreichungsform bringt.
  22. Verwendung von Verbindungen der Formel I gemäss Anspruch 1 und ein pharmazeutisch annehmbares Säureadditionssalz davon zur Herstellung eines Medikaments für die Behandlung von Gedächtnisstörungen im Zusammenhang mit der Alzheimer-Krankheit oder von altersbedingten Verschlechterungen des Erinnerungsvermögens.
  23. Verbindungen der Formeln
    Figure imgb0138
     worin R₁' (C₁-C₇)Alkyl oder Aryl(C₁-C₇)alkyl bedeutet.
  24. Verbindungen der Formel
    Figure imgb0139
     worin Z Aryl oder
    Figure imgb0140
     R₁' (C₁-C₇)Alkyl oder Aryl(C₁-C₇)alkyl, R₃ und R₄ die in Anspruch 1 angegebenen Bedeutung haben und R₆' (C₁-C₇)Alkyl oder Aryl(C₁-C₇)alkyl bedeuten.
  25. Verbindungen der Formel
    Figure imgb0141
     worin R₁, R₂, R₃ und R₄ die in Anspruch 1 angegebene Bedeutung haben, sowie Acylhalogenide, gemischte Anhydride oder aktive Ester davon.
  26. Verbindungen der Formel
    Figure imgb0142
     worin R₁' (C₁-C₇)Alkyl oder Aryl(C₁-C₇)alkyl bedeutet.
EP90100935A 1989-01-17 1990-01-17 Cyclohexanacetamid-Derivate Expired - Lifetime EP0381959B1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US377643 1982-05-13
US29772689A 1989-01-17 1989-01-17
US297726 1989-01-17
US37764389A 1989-07-10 1989-07-10

Publications (2)

Publication Number Publication Date
EP0381959A1 EP0381959A1 (de) 1990-08-16
EP0381959B1 true EP0381959B1 (de) 1995-05-03

Family

ID=26970288

Family Applications (1)

Application Number Title Priority Date Filing Date
EP90100935A Expired - Lifetime EP0381959B1 (de) 1989-01-17 1990-01-17 Cyclohexanacetamid-Derivate

Country Status (16)

Country Link
EP (1) EP0381959B1 (de)
JP (1) JPH02229154A (de)
KR (1) KR900011759A (de)
AT (1) ATE122037T1 (de)
AU (1) AU625157B2 (de)
CA (1) CA2007732A1 (de)
DE (1) DE69019007T2 (de)
DK (1) DK0381959T3 (de)
ES (1) ES2071685T3 (de)
FI (1) FI900231A0 (de)
HU (1) HUT53607A (de)
IL (1) IL93051A0 (de)
MC (1) MC2081A1 (de)
NO (1) NO174386C (de)
NZ (1) NZ232112A (de)
PT (1) PT92874A (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100395779B1 (ko) * 2001-05-25 2003-08-21 한국화학연구원 임의적으로 베타-위치가 치환된 알파-아릴알킬기의 제거를통해 3급 아미드 화합물로부터 2급 아미드 화합물을제조하는 방법
CA2740610C (en) 2008-10-16 2020-01-07 The Johns Hopkins University Synaptic vesicle protein 2a inhibitors for treating age-related cognitive impairment
EP3610890A1 (de) 2012-11-14 2020-02-19 The Johns Hopkins University Verfahren und zusammensetzungen zur behandlung von schizophrenie
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
DK2968220T3 (da) 2013-03-15 2021-06-14 Agenebio Inc Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion
CN112843005B (zh) 2015-05-22 2023-02-21 艾吉因生物股份有限公司 左乙拉西坦的延时释放药物组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2635853A1 (de) * 1975-08-13 1977-02-24 Isf Spa Pyrrolidin-2-on-derivate, verfahren zu ihrer herstellung und sie enthaltendes arzneimittel

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3336024A1 (de) * 1983-10-04 1985-04-18 Boehringer Ingelheim KG, 6507 Ingelheim 4-amino-l-benzyl-pyrrolidinone und ihre saeureadditionssalze, verfahren zu ihrer herstellung und arzneimittel
US4668687A (en) * 1984-07-23 1987-05-26 Bristol-Myers Company Psychogeriatric 1-(2-pyrimidinyl)piperazinyl derivatives of 1-pyrrolidin-2-ones
IT1190378B (it) * 1985-06-21 1988-02-16 Isf Spa Derivati pirrolidonici
IT1224168B (it) * 1986-08-01 1990-09-26 Finanziaria R F Spa Ora Finanz Derivati del pirrolidin-2-one ad attivita' nootropa

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2635853A1 (de) * 1975-08-13 1977-02-24 Isf Spa Pyrrolidin-2-on-derivate, verfahren zu ihrer herstellung und sie enthaltendes arzneimittel

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS vol. 109, no. 17, 24 October 1988, page 716, abstract no. 149339u, Columbus, Ohio, US; & JP-A-62 116 557 (TAKEDA CHEMICAL IND., LTD.) 28.05.1987 *
CHEMICAL ABSTRACTS, vol. 106, no. 5, 2 February 1987, page 529, abstract no. 32828z, Columbus, Ohio, US; & ES-A-534 274 (LABORATORIO FARMACEUTICO QUIMICO-LAFARQUIM S.A.) 16.10.1985 *
CHEMICAL ABSTRACTS, vol. 67, no. 1, 3 July 1967, page 275, abstract no. 2960v, Columbus, Ohio, USA; T. MUNEMITSU et al.: "A synthesis of 5-benzyl-2-pyrrolidinone" & Yakugaku Zasshi 1966, vol. 86, no. 12, pages 1213-1216 *
TETRAHEDRON LETTERS, vol. 28, no. 14, pages 1573-1576, Oxford, GB; T.L. GILCHRIST et al.: "Selective reduction and cleavage of the N-N bond of fused tetrahydropyridazines: A route to functionalised lactams". *

Also Published As

Publication number Publication date
HUT53607A (en) 1990-11-28
IL93051A0 (en) 1990-11-05
HU900127D0 (en) 1990-03-28
NO900234D0 (no) 1990-01-16
NO900234L (no) 1990-07-18
DK0381959T3 (da) 1995-09-04
EP0381959A1 (de) 1990-08-16
NO174386B (no) 1994-01-17
ES2071685T3 (es) 1995-07-01
MC2081A1 (fr) 1991-01-07
PT92874A (pt) 1990-07-31
AU625157B2 (en) 1992-07-02
NO174386C (no) 1994-04-27
KR900011759A (ko) 1990-08-02
JPH02229154A (ja) 1990-09-11
ATE122037T1 (de) 1995-05-15
CA2007732A1 (en) 1990-07-17
AU4798890A (en) 1990-07-26
DE69019007T2 (de) 1995-09-14
FI900231A0 (fi) 1990-01-16
NZ232112A (en) 1992-07-28
DE69019007D1 (de) 1995-06-08

Similar Documents

Publication Publication Date Title
Brenner et al. Enantioselective preparation of γ‐amino acids and γ‐lactams from nitro olefins and carboxylic acids, with the valine‐derived 4‐Isopropyl‐5, 5‐diphenyl‐1, 3‐oxazolidin‐2‐one as an auxiliary
RU2168497C2 (ru) Новые производные гидроксамовой кислоты, полезные для лечения заболеваний, связанных с дегенерацией соединительной ткани
US6566553B2 (en) Synthesis of clasto-lactacystin β-lactone and analogs thereof
HU193876B (en) Process for preparing cycloalkane /c/ pyrrol-1-carboxypeptides and pharmaceutics comprising the same
EP1660443A2 (de) Cyclische amine mit benzamidsubstituent als bace-1-inhibitoren
US5281612A (en) Naphthyridine antibacterial agents
KR20140085576A (ko) 5-바이페닐-4-아미노-2-메틸 펜탄산의 제조 방법
AU2006301470A1 (en) Prolinamide derivatives as sodium channel modulators
JPS61502818A (ja) シス、エンド−オクタヒドロシクロペンタ〔ｂ〕ピロ−ル−２−カルボキシレ−トの新規製造方法
US5053422A (en) Psychotropic perhydroazacycloalka [1,2-A] imidazole derivatives
Alcaraz et al. Asymmetric syntheses of 1-amino-2-phenyl (alkyl) cyclopropanecarboxylic acids by diastereoselective cyclopropanation of highly functionalized monochiral olefines
EP0381959B1 (de) Cyclohexanacetamid-Derivate
EP2358670B1 (de) Ein Verfahren zur Herstellung von tert-butyl (R)-3-vinylpyrrolidin-1-carboxylat und dafür geeignete Zwischenprodukte
Knight et al. β-Hydroxypiperidinecarboxylates: additions to the chiral pool from bakers’ yeast reductions of β-ketopiperidinecarboxylates
AU651495B2 (en) New nitrogen-containing bicyclic compounds, process for preparing them and pharmaceutical compositions containing them
EP0559774B1 (de) Individuelle stereoisomere von 7-[3-(aminoalkyl)-1-pyrrolidinyl]-quinolone und naphthyridone als antibakterielle wirkstoffe
CA1337770C (en) Hydrocarbon substituted pyrrolidinones
US5015653A (en) [(5-oxo)-2-pyrrolidinyl)methyl]cyclohexaneacetamides, compositions and use
Rashid et al. Synthesis of novel 3, 4-fused pyrazolidinone γ-lactam bicyclic moieties from 2, 3-dioxo-4-carboxy-5-(substituted) pyrrolidines
US4550104A (en) Antibacterial thiazolo-quinolines and thiazolo-naphthyridines
EP0255149A1 (de) Pyrrolidin-2-on-Derivate mit nootroper Aktivität
JPH0128019B2 (de)
Otto Optically Active α-Spirocyclopropyllactones and 3-Aminopyrrolidones via Stereoselective Diazoalkane Cycloaddition at α-Alkylidenelactones
JPH08501306A (ja) キラルなキノロン誘導体
EP1682546B1 (de) Peptidomimetische verbindungen, stereoselektives verfahren zu deren herstellung und deren verwendung als biologisch wirksame synthesezwischenprodukte

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19900117

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19920901

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19950503

REF Corresponds to:

Ref document number: 122037

Country of ref document: AT

Date of ref document: 19950515

Kind code of ref document: T

REF Corresponds to:

Ref document number: 69019007

Country of ref document: DE

Date of ref document: 19950608

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2071685

Country of ref document: ES

Kind code of ref document: T3

ITF It: translation for a ep patent filed

Owner name: BARZANO' E ZANARDO MILANO S.P.A.

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19950803

ET Fr: translation filed
REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19960131

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19990111

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 19990113

Year of fee payment: 10

Ref country code: AT

Payment date: 19990113

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19990121

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 19990125

Year of fee payment: 10

Ref country code: DE

Payment date: 19990125

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19990131

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19990210

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19990324

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000117

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000117

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000117

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000118

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000131

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000131

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000131

BERE Be: lapsed

Owner name: F. HOFFMANN-LA ROCHE A.G.

Effective date: 20000131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000801

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20000117

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000929

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20000801

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20001101

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20011010

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050117